Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai MicroPort MedBot (Group) Co., Ltd.
上海微创医疗机器人(集团)股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT
TOUMAI LAPAROSCOPIC SURGICAL ROBOT COMMERCIAL ORDERS EXCEEDING 400 UNITS WORLDWIDE

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders of the Company (the "**Shareholders**") and potential investors the updates on the latest business development of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, as of the date of this announcement, the cumulative number of commercial orders for the Group's core product, the Toumai Laparoscopic Surgical Robot ("**Toumai**"), has exceeded 400 units worldwide. Specifically, in the PRC market, Toumai secured 37 new orders within the year, covering national medical centres, leading provincial-level hospitals, and premium private hospitals. According to public data, Toumai ranked first in the entire industry in terms of new orders within the year, marking the first time that a single brand has achieved an annual order volume surpassing that of international brands since the initial commercialisation of domestically-produced laparoscopic surgical robots. In overseas markets, Toumai secured more than 200 commercial orders this year, expanding its presence to over 70 countries and regions; according to public data, it continued to hold the No. 1 market position among domestic brands and rank among the global top two comparable brands.

It took only 13 months for Toumai's commercial orders to increase from 100 to 400 units. With the continued deepening of its global market footprint, Toumai has become the only surgical robot brand actively performing clinical applications in over 20 countries. Meanwhile, in several countries including the PRC, Belgium, India, Morocco, Brazil, Argentina, and Armenia, single medical institutions have achieved "repeat purchases" of Toumai, indicating that Toumai has moved beyond the market access and initial application stages, transitioning into deeper clinical penetration and large-scale deployment.

To support the rapid growth of its global installed base and the scaled implementation of clinical applications, the Group has established a professional training network covering six continents of the world. To date, the number of Toumai global training centres has reached nearly 70, with an annual training capacity exceeding 2,000 trainees. The training covers surgeons as well as nursing, sterile supply, and technical support teams. In the PRC, the Group has established over 40 training centres in partnership with medical institutions; overseas, in addition to collaborating with internationally renowned training institutions such as the ORSI Academy and IRCAD, the Group has also leveraged its regional headquarters located in Turkey, Brazil, and other regions to further extend training resources to surrounding markets.

In the field of remote surgery, Toumai has been approved in nearly 60 countries and regions worldwide, and has helped more than 30 countries and regions, including the United States, the United Kingdom, France, Germany, Spain, Italy, Brazil and Argentina, achieve their "zero breakthroughs" in terms of remote surgeries. Its global remote surgical collaboration network now covers six continents, namely Asia, Europe, Africa, South America, North America and Oceania, continuously advancing remote surgery from technological innovation towards cross-regional, cross-border and even intercontinental clinical practice.

At the academic level, an academic article has been published in *npj Digital Surgery*, a Nature portfolio journal, featuring a transcontinental remote robotic surgery procedure between the United States and Angola assisted by Toumai as a case study. This reflects that remote surgery is moving beyond the validation of technical feasibility towards standardised and sustainable clinical applications. In October this year, Dr. Vipul Patel, an international robotic surgery expert, completed the first remote surgery performed within the United States using Toumai under the FDA IDE clinical study framework, attracting attention from the global surgical community and the media.

The Board is of the view that Toumai commercial orders exceeding 400 units worldwide and the continued expansion of its overseas market coverage reflect the further maturity of the clinical value, brand recognition and global channel deployment of the Group's products, which will help consolidate the Group's future revenue base and have a positive impact on the long-term development of the Group's business.

The Board wishes to remind Shareholders and potential investors that the above information is unaudited and based on preliminary internal information and public data of the Group, which may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company on an annual or half-yearly basis due to various uncertainties during the process of collating such information.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange was suspended from 9:00 a.m. on Tuesday, 1 September 2026 and will be suspended until further announcement. The suspension will remain in force until further notice.

The Company would like to emphasise that the Group's operations remain stable and have not been affected in any way.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Chao He
Executive Director

Shanghai, China, 24 November 2026

As at the date of this announcement, the executive director is Dr. Chao He, the non-executive directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.